Abstract
Neuroblastoma is a cancer of the sympathetic nervous system. This is a solid malignant tumour which resides as an accumulation in the abdomen or around the spinal cord in the neck, chest, or pelvis. Chemotherapy and radiation are standard treatments for the neuroblastoma patients, however relapses are common and more difficult to treat, making neuroblastoma one of the most lethal of all childhood cancers. Furthermore, the application of these therapies is restricted by dose-limiting toxicities and little tumour specificity. Recently, there has been an increase in interest in the use of biological immune-based therapies for patients with malignancies, including neuroblastoma. This has been determined by a deeper understanding of the crosstalk between the host immune system and malignant tumours, as well as a number of potential advantages of immunotherapy – high specificity and less toxicity than standard approaches. The particular emphasis of this article is on the advantages and current drawbacks of antibody-based immunotherapy for neuroblastoma. This review discusses the issues with a view to inspiring the development of new agents that could be useful for the treatment of neuroblastoma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bartolotti S, Peters D (1978) Delayed removal of renal-bound antigen in decomplemented rabbits with acute serum sickness. Clin Exp Immunol 32:199–206
Brennan P, Donev R, Hewamana S (2008) Targeting transcription factors for therapeutic benefit. Mol Biosyst 4:909–919
Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945–954
Buettner R, Huang M, Gritsko T, Karras J, Enkemann S, Mesa T, Nam S, Yu H, Jove R (2007) Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 5:823–832
Chen S, Caragine T, Cheung N, Tomlinson S (2000a) Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. Am J Pathol 156:1085–1091
Chen SH, Caragine T, Cheung NKV, Tomlinson S (2000b) CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res 60:3013–3018
Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J, Introna M (2001) Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114:800–809
Donev RM, Cole DS, Sivasankar B, Hughes TR, Morgan BP (2006) p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res 66:2451–2458
Donev R, Gray L, Sivasankar B, Hughes T, van den Berg C, Morgan BP (2008) Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. Cancer Res 68:5979–5987
Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109–123
Gelderman KA, Lam S, Sier CF, Gorter A (2006) Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity. Eur J Immunol 36:977–984
Gillies S, Reilly E, Lo K, Reisfeld R (1992) Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89:1428–1432
Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies S, Reisfeld R, Neithammer D (1995) A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A:261–267
Harris C, Kan K, Stevenson G, Morgan BP (1997) Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clin Exp Immunol 107:364–371
Holla VR, Wang D, Brown JR, Mann JR, Katkuri S, DuBois RN (2005) Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J Biol Chem 280:476–483
Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS (2007) Decay accelerating factor can control T cell differentiation into IFN-γ-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol 179:5793–5802
Liu J, Miwa T, Hilliard B, Chen Y, Lambris J, Wells A, Song W (2005) The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201:567–577
Lode H, Xiang R, Dreier T, Varki N, Gillies S, Reisfeld R (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706–1715
Lublin DM, Atkinson JP (1989) Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 7:35–58
Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F (2007) In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67:10556–10563
Mason JC, Steinberg R, Lidington EA, Kinderlerer AR, Ohba M, Haskard DO (2004) Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2) and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A. J Biol Chem 279:41611–41618
Mujoo K, Cheresh D, Yang H, Reisfeld R (1987) Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 47:1098–1104
Mulé J, Yang J, Afreniere R, Shu S, Rosenberg S (1987) Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 139:285–294
Munn D, Cheung N (1987) Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47:6600–6605
Ohta S, Igarashi S, Honda A, Sato S, Hanai N (1993) Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies. Anticancer Res 13:331–336
Sondel P, Hank J, Gan J, Neal Z, Albertini M (2003) Preclinical and clinical development of immunocytokines. Curr Opin Investig Drugs 4:696–700
Spiller OB, Criado-Garcia O, Rodriguez De Cordoba S, Morgan BP (2000) Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol 121:234–241
Spix C, Aareleid T, Stiller C, Magnani C, Kaatsch P, Michaelis J (2001) Survival of children with neuroblastoma: time trends and regional differences in Europe, 1978–1992. Eur J Cancer 37:722–729
Svennerholm L, Boström K, Fredman P, Jungbjer B, Lekman A, Månsson J, Rynmark B (1994) Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1214:115–123
Thomas P, Delatte S, Sutphin A, Frankel A, Tagge E (2002) Effective targeted cytotoxicity of neuroblastoma cells. J Pediatr Surg 37:539–544
Varela J, Imai M, Atkinson C, Ohta R, Rapisardo M, Tomlinson S (2008) Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res 68:6734–6742
Walport MJ (2001) Advances in immunology: complement (First of two parts). N Engl J Med 344:1058–1066
Yeh S, Larson S, Burch L, Kushner B, Laquaglia M, Finn R, Cheung N (1991) Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med 32:769–776
Yu H, Jove R (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4:97–105
Zell S, Geis N, Rutz R, Schultz S, Giese T, Kirschfink M (2007) Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol 150:576–584
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Donev, R.M., Hughes, T.R., Morgan, B.P. (2012). Neuroblastoma: Antibody-Based Immunotherapy. In: Hayat, M. (eds) Neuroblastoma. Pediatric Cancer, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2418-1_10
Download citation
DOI: https://doi.org/10.1007/978-94-007-2418-1_10
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2417-4
Online ISBN: 978-94-007-2418-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)